
Various HIV protease crystals used for fragment screening and data collection at SSRL.
HIV protease (PR) is a proven target for drugs that suppress HIV AIDS, but treatment leads to multi-drug-resistant mutants. As a strategy to defeat the evolution of viral resistance, we are employing fragment based lead discovery to develop novel classes of allosteric PR inhibitors able to act in synergy with FDA approved drugs.

Electron density for a chemical "fragment" bound in a pocket on the surface of HIV protease when the active site is occupied with an inhibitor.
California: 10550 North Torrey Pines Road, La Jolla, CA 92037 - (858) 784-1000
Florida: 130 Scripps Way, Jupiter, FL 33458 - (561) 228-2000
Copyright © 2013, The Scripps Research Institute (TSRI). All Rights Reserved.
